• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Nektar Therapeutics - Product Pipeline Review - Q4 2010 Product Image

Nektar Therapeutics - Product Pipeline Review - Q4 2010

  • ID: 1463929
  • December 2010
  • 91 pages
  • Global Markets Direct

Nektar Therapeutics – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Nektar Therapeutics - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Nektar Therapeutics - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Nektar Therapeutics human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, READ MORE >



List of Tables
List of Figures
Nektar Therapeutics Snapshot
Nektar Therapeutics Overview
Key Information
Key Facts
Nektar Therapeutics – Research and Development Overview
Key Therapeutic Areas
Nektar Therapeutics – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Nektar Therapeutics – Pipeline Products Glance
Nektar Therapeutics Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Nektar Therapeutics–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Nektar Therapeutics – Drug Profiles
NKTR-102
Product Description
Mechanism of Action
R&D Progress
NKTR-102 + Cetuximab
Product Description
Mechanism of Action
R&D Progress
Oral NKTR-118
Product Description
Mechanism of Action
R&D Progress
NKTR-063
Product Description
Mechanism of Action
R&D Progress
NKTR-102 + 5-Fluorouracil
Product Description
Mechanism of Action
R&D Progress
NKTR-105
Product Description
Mechanism of Action
R&D Progress
Longer-Acting rFVIII
Product Description
Mechanism of Action
R&D Progress
NKTR-125
Product Description
Mechanism of Action
R&D Progress
NKTR-140
Product Description
Mechanism of Action
R&D Progress
NKTR-171
Product Description
Mechanism of Action
R&D Progress
NKTR-181
Product Description
Mechanism of Action
R&D Progress
NKTR-194
Product Description
Mechanism of Action
R&D Progress
Oral NKTR-119
Product Description
Mechanism of Action
R&D Progress
Nektar Therapeutics – Pipeline Analysis
Nektar Therapeutics – Pipeline Products by Therapeutic Class
Nektar Therapeutics Pipeline Products By Target
Nektar Therapeutics – Pipeline Products by Route of Administration
Nektar Therapeutics – Pipeline Products by Molecule Type
Nektar Therapeutics – Recent Pipeline Updates
Nektar Therapeutics - Dormant Projects
Nektar Therapeutics – Company Statement
Nektar Therapeutics – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Dec 09, 2010: Nektar To Present Phase II Clinical Data On NKTR-102 At Annual CTRC-AACR San Antonio Breast Cancer Symposium
Oct 15, 2010: Nektar Presents NKTR-181 Preclinical Data At Pain 2010 Conference
Jul 06, 2010: Nektar's NKTR-102 Demonstrates Superior Activity To Irinotecan In Nonclinical Studies In Tumor Models Of Gastrointestinal Cancer
Jul 06, 2010: Nektar Presents Data On NKTR-102 In Nonclinical Studies In Tumor Models Of Gastrointestinal Cancers At ESMO
Jun 24, 2010: Nektar Doses First Patients In Phase I Study Of NKTR-102 In Combination With 5-Fluorouracil/Leucovorin
Jun 09, 2010: Nektar Announces Positive Phase II Study Results Of NKTR-102 In Metastatic Breast Cancer
Jun 06, 2010: Nektar Announces NKTR-102 Positive Phase II Results In Platinum-Resistant/Refractory Ovarian Cancer
May 20, 2010: Nektar's NKTR-102 Phase II Clinical Data Accepted For Oral Presentation At 2010 ASCO Annual Meeting
Mar 09, 2010: Nektar Reports Positive Phase II Clinical Data From First Stage Of NKTR-102 Study In Women With Platinum-Resistant Ovarian Cancer
Jan 12, 2010: Nektar Therapeutics Announces first Stage Phase 2 Study Results Of NKTR-102 In Platinum-Resistant Ovarian Cancer
Financial Deals Landscape
Nektar Therapeutics, Deals Volume Summary, 2004 to YTD 2010
Nektar Therapeutics, Deals Summary By Region, 2004 to YTD 2010
Nektar Therapeutics, Deals Summary, 2004 to YTD 2010
Nektar Therapeutics Detailed Deal Summary
Asset Purchase
Novartis Acquires Pulmonary Drug-Delivery Business Unit Of Nektar Therapeutics
Acquisition
Nektar Therapeutics Acquires Aerogen
Private Equity
Aerogen Completes Management Buyout
Venture Financing
Pearl Therapeutics Secures Additional $18 Million In Series A Financing
Equity Offering
Nektar Therapeutics Completes Private Placement Of $8 Million
Nektar Therapeutics Completes Private Placement Of $24 Million
Nektar Therapeutics Completes Public Offering Of $197 Million
Debt Offering
Nektar Therapeutics Completes Private Placement Of 3.25% Convertible Subordinated Notes For $315 Million
Nektar Therapeutics Enters Into Co-Development Agreement With Baxter International
Nektar Therapeutics Enters Into Co-Development Agreement With Bayer HealthCare
Nektar Therapeutics Signs Co-Development Agreement With Bayer HealthCare
Nektar Therapeutics Enters Into Co-Development Agreement With Baxter International
Biota Holdings Enters Into Co-Development Agreement With Aerogen
Nektar Therapeutics Enters Into An Agreement With Bayer HealthCare
Nektar Therapeutics Enters Into Co-Development Agreement With Zelos Therapeutics
Respironics Enters Into Co-Marketing Agreement With Nektar Therapeutics
Aerogen Enters Into An Agreement With MAQUET Critical Care
SciClone Pharmaceuticals Enters Into Co-Development Agreement With Nektar Therapeutics
Nektar Therapeutics Terminates Co-Development Agreement With Pfizer
Licensing Agreements
Nektar Therapeutics Enters Into Licensing Agreement With AstraZeneca
Nektar Therapeutics Enters Into Licensing Agreement With Pfizer
Nektar Therapeutics Enters Into Licensing Agreement With GlaxoSmithKline
Nektar Therapeutics Enters Into Licensing Agreement With Affymax
Nektar Therapeutics Enters Into Licensing Agreement With Roche
Nektar Therapeutics Terminates Licensing Agreement With Celltech Group
Enzon Pharmaceuticals Terminates Licensing Agreement With Nektar Therapeutics
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS